Why is Brawn Biotech falling/rising?

As of 26-Aug, Brawn Biotech Ltd's stock price is currently at 21.75, reflecting an increase of 0.95 or 4.57%. The stock has shown strong performance recently, gaining 15.08% over the last three days and outperforming its sector by 6.54% today. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating positive momentum. Despite the stock's recent gains, it faces challenges with weak long-term fundamentals, including an average Return on Equity (ROE) of 0% and declining net sales and operating profit over the past five years. Additionally, the company's ability to service its debt is concerning, as indicated by a poor EBIT to Interest ratio of -1.22.
In the broader market context, Brawn Biotech has significantly outperformed the benchmark, with a 1-week return of +20.83% compared to the Sensex's -1.05%. Over the past year, while the stock has generated a return of 13.70%, the broader market has seen negative returns of -1.12%. This contrast highlights the stock's resilience despite the overall market's struggles. However, the stock's performance is tempered by its risky profile, as it has a negative EBITDA and has not demonstrated sustainable long-term growth, which could impact investor sentiment moving forward.